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Abstract Application of tetrameric MHC class I-peptide
complexes has signiWcantly improved the monitoring of
antigen-speciWc T cell immune responses in mouse models
as well as in clinical studies. Especially MHC class I tetra-
mer analysis of tumor-speciWc T cells in suspension or on
thick vibratome sections from viable tissue has been proven
extremely useful. Using the well-characterized mouse
tyrosinase-related-protein-2 speciWc cytotoxic T cell (CTL)
clone LP9, we now developed a method that allows for
speciWc identiWcation of T cells with MHC class I tetramers
in 8 m thick, chemically Wxed cryosections. The protocol
was validated in a murine inXuenza virus-infection model.
Moreover, analysis of delayed type hypersensitivity (DTH)
skin biopsies from melanoma patients vaccinated with
peptide-loaded mature dendritic cells, revealed the presence
and location of anti-tumor CTLs. The speciWcity of the
CTLs detected in situ correlated with both the DTH
challenge speciWcity and reactivity of cell suspensions
derived from the same biopsies. Collectively, our data dem-
onstrate that in situ MHC class I tetramer staining provides
a valuable tool to reveal the presence and anatomical loca-
tion of speciWc CTLs in frozen tissue following immune-
based treatment strategies in cancer patients.
Introduction
Immune-based treatment strategies are considered a valu-
able treatment option for cancer patients. Objective responses
have been obtained with a variety of immunotherapy
approaches especially in melanoma patients [18, 20].
Recently dendritic cell (DC)-based vaccination studies have
received increasing attention and yielded promising results
in cancer patients [5, 13, 16, 17, 19, 32]. Development and
validation of immunologically based treatment strategies is,
however, critically dependent on appropriate monitoring of
both the immunological response and the clinical response
to deWne the correlates of treatment eYcacy [6, 25]. The
availability of soluble multimeric MHC-peptide complexes
has broadened the options for immune monitoring since spe-
ciWc CTLs can be identiWed and isolated directly [1, 22, 34].
In most studies MHC class I tetramers were only eVective
for analysis of T cells that are in suspension [24, 26]. How-
ever, like for functional T cell assays, e.g., ELI-spot assay
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1668 Cancer Immunol Immunother (2007) 56:1667–1676and cytotoxicity assay, this does not yield any information
regarding the localization of speciWc T cells within tissues
[7, 8, 15, 23]. Therefore, in situ detection of speciWc T cells
in tissues would be highly informative in revealing the loca-
tion and unraveling possible mechanisms of the anti-tumor
response in vivo. In this paper we report on the development
of a protocol that allows for in situ detection of antigen spe-
ciWc T-cells in frozen and Wxed tissue sections. The protocol
was Wrst developed using mouse H-2Kb-TRP2180 tetramers
and a mouse tissue model containing TRP2-speciWc CTLs
[28]. Validation of the protocol was performed in a murine
viral infection model and in delayed type hypersensitivity
(DTH) biopsies from melanoma patients treated with tumor
peptide-loaded DCs [9].
Materials and methods
MHC class I tetramers
Tetrameric, MHC class I-peptide complexes with speciWci-
ties for mouse H-2Kb-TRP2180–187, H-2Kb-OVA257–264,
H-2Db-inXuenza A virus NP366–374, and human HLA-A2.1-
gp100154–162; HLA-A2.1-gp100280–288 and HLA-A2.1-tyrosi-
nase369–377 were kindly provided by Drs T. Schumacher and
H. Spits from the Netherlands Cancer Institute (Amster-
dam, The Netherlands) or purchased from Immunomics,
Beckman Coulter (Inc, San Diego, USA). Other MHC class
I tetramers; HLA-A2.1-MART-126–35, HLA-A2.1-HIV-
gag77–85 and HLA-A2.1-EBV280–288 were purchased from
Immunomics. Each MHC class I tetramer was validated by
staining of a CTL line speciWc for HLA-A2.1 in association
with the peptide of interest.
Antibodies
Primary antibodies used for the detection of CD8+ cells
were WT82 [21] and HIT8a (BD Pharmingen). Secondary
antibodies used: biotinylated rabbit anti-streptavidin (code
200–4695), rabbit anti-phycoerythrin (code 200–4199),
rabbit anti-streptavidin (code 200–4195) purchased from
Rockland Gilbertville, Pa, mouse anti-streptavidin (clone
DD9; Upstate Biotechnology) and goat anti-streptavidin
(Biogenesis, Poole, UK), goat-anti-rabbit-Alexa594, goat-
anti-mouse-Alexa498 (Molecular Probes, Europe BV,
Leiden, The Netherlands).
Tissues
For development and optimization of a protocol suitable for
in situ detection of CTLs we used the H-2Kb-restricted
TRP2-speciWc clone LP9 [28]. LP9 cells were injected in the
hind leg muscles of C57Bl6 mice. After 5 min the mice were
sacriWced and the injected muscles were dissected, snap fro-
zen in liquid nitrogen and stored at ¡80°C until further use.
For validation of the optimized protocol developed with
the LP9-containing muscle tissue, staining with MHC class
I tetramers was also performed on spleens from virus-
infected and non-infected B6.Ly5.1 mice and on biopsies
from DTH lesions from melanoma patients.
The spleens from B6.Ly5.1 mice were kindly provided
by Drs F. Vyth-Dreese and T. Schumacher from the Neth-
erlands Cancer Institute (Amsterdam, The Netherlands). In
this virus infection model B6.Ly5.1 mice had received an
adoptive transfer of B10F5 lymph node cells. B10F5 mice
are transgenic for the H-2Db-restricted, inXuenza A virus
NP366-speciWc, TCR [14]. Three days after adoptive trans-
fer, part of the mice were infected with inXuenza A virus.
Ten days after adoptive transfer spleens were isolated from
infected and non-infected mice.
In situ staining with MHC class I tetramer
From snap frozen material (muscles or biopsies) 8 m thick
cryosections were cut and air-dried and used immediately
or stored at ¡80°C until use. Tissue sections were Wxed
with 4% paraformaldehyde (PFA) for 3 min. Non-speciWc
protein binding was prevented by using 20% normal goat
serum in PBS for 20 min. Incubation with MHC class I tet-
ramer was performed overnight at 4°C at an approximate
MHC class I tetramer concentration of 5 M in 4% normal
goat serum and PBS. After washing with PBS speciWc
MHC class I tetramer binding was Wxed with 4% PFA for
20 min. Sections were incubated with or without anti-CD8
at a concentration of 2 g/ml and after washing they were
incubated with polyclonal rabbit serum against streptavi-
dine (1/800 diluted, Rockland). Binding of MHC class I
tetramer was visualized using a polyclonal goat-anti-rabbit-
Alexa594 at a 1/500 dilution, resulting in a red Xuorescent
signal. CD8 was visualized using a polyclonal goat-anti-
mouse-Alexa498 (1/500 dilution; 30 min at room tempera-
ture), resulting in a green Xuorescent signal.
Sections were counterstained with DAPI resulting in a
blue Xuorescent staining of the nucleus. Washing in PBS
was performed between each incubation. Finally, sections
were then mounted with Xuorescent mounting medium con-
taining anti-fade.
FITC and TRITC signals were collected on a Leica Leitz
DMRBE. Images were taken using a £10, £40 or £63
objective. Color photomicrographs were generated from
electronic overlays.
Patients
Melanoma patients (stage III and IV according to AJCC
criteria [4]) participating in ongoing protocols, in which the123
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included [10]. Eligibility criteria included HLA-A2.1 phe-
notype, melanoma expressing gp100 and tyrosinase, and
WHO performance status 0 or 1. Additional eligibility cri-
teria are described previously. The studies were approved
by the local regulatory committee, and written informed
consent was obtained from all patients.
Delayed type hypersensitivity
One to 2 weeks after DC vaccination, a DTH skin test was
performed. BrieXy, unpulsed DC, DC pulsed with the indi-
cated peptides, DC pulsed with KLH, and DC pulsed with
the indicated peptides plus KLH (2–10 £ 105 DC each)
were injected i.d. [9].
Fig. 1 In situ detection of antigen-speciWc T cells. Flow cytometric
analysis of tetramer binding by LP9 T cells, control tetramer H-2Kb-
OVA (a) and relevant tetramer H-2Kb-TRP2180 (b). Positive staining of
a cytological preparation containing LP9 cells and normal C57BL
splenocytes was only observed with H-2Kb-TRP2180 tetramer (c) and
not without tetramer (negative control) (d). Staining of normal
splenocytes with H-2Kb-TRP2180 tetramer did not result in a positive
signal (e). H&E-stained section of LP9-containing muscle tissue (f).
Improved morphology and signal to noise ratios of in situ detection of
antigen speciWc T cells in LP9-containing muscle tissue sections
stained histochemically with speciWc tetramers (j–l) or negative
control solution (without tetramer) (g–i) using the ABC-peroxidase kit
with AEC (red-brown staining) as substrate. g, j Without blocking
with normal goat serum and PFA-Wxation prior to staining. h, k With
normal goat serum blocking but without PFA-Wxation prior to staining.
i, l With blocking with normal goat serum and PFA-Wxation prior to
staining. LP9-containing muscle tissue sections stained with or without
tetramers with Xuorescent microscopy visualization. Positive staining
was observed after incubation with speciWc H-2Kb-TRP2180 tetramers
(m) and not without the addition of tetramer (n) or after incubation
with control tetramer H-2Kb-OVA123
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(6 mm) were obtained and cut in half; one part was
embedded in Tissue-tek, snap frozen in liquid nitrogen
and stored at ¡80°C until further use. The other part was
cut in pieces and cultured in RPMI/7%HS supplemented
with IL-2 (100 U/ml). Every 7 days, half of the medium
was replaced by fresh IL-2-containing RPMI/7%HS.
After 2–4 weeks of culturing, T cells were tested for
speciWcity.
MHC class I tetramer staining of cells in suspension
DTH-derived cells (1 £ 105 cells in 10 l) or PBMC
(1 £ 106 cells in 10 l) were incubated with PE-labeled
MHC class I tetramers and FITC-conjugated mAbs either
directed against CD4 or CD8 (both Becton Dickinson) for
1 h at RT. After washing, the samples were analyzed by
Xow cytometry.
Cytotoxicity assay
Cytotoxic activity of DTH-inWltrated lymphocytes was
measured using the chromium release assay as described
previously [3]. BrieXy, T2 or BLM cells (a melanoma cell
line expressing HLA-A2.1 and no endogenous expression
of gp100 and tyrosinase), transfected with control antigen
G250, or with the antigens of interest (gp100 and tyrosi-
nase) were incubated with 100 Ci Na2[51Cr]O4 (Amersham,
Bucks, UK) and, after washing, added to lymphocytes (105
cells) and unlabeled K562 cells (104 cells) in triplicate
wells of a round bottom microtiter plate (E/T ratio 10/1).
After 4 h, supernatants were harvested and radioactivity
was measured. The speciWc percentage of cytotoxicity was
deWned by: [(experimental release ¡ spontaneous release) ¥
(maximum release ¡ spontaneous release)] £ 100%.
Results and discussion
In situ detection of antigen speciWc T cells with MHC class 
I tetramers: protocol requirements
To develop a protocol that allows in situ detection of
CTLs with MHC class I tetramers on cryo-sections, we
used the well-characterized H-2Kb-restricted TRP2180-
speciWc CTL clone LP9 and the corresponding H-2Kb-
TRP2 tetramers [28]. As shown in Fig. 1 A-B, LP9 CTLs
in suspension were readily stained by TRP2-speciWc tetra-
mers but not by OVA-speciWc tetramers recognizing the
OVASIINFEKL peptide presented by the same H-2Kb mole-
cule. For immunocytochemical stainings, cytospins were
generated of LP9 cells, either alone or mixed with C57Bl6
thymocytes. ArtiWcial tissues containing LP9 CTLs were
obtained by injection of these CTLs in femoral muscles of
C57Bl6 mice, and freezing of the dissected injection site.
To detect CTLs, cytospins (Fig. 1c–e) and artiWcial
Fig. 2 In situ detection of a 
virus-speciWc response. Tissue 
sections from spleens derived 
from mice that received adoptive 
transfer with H-2Db-NP366 
transgenic lymph node cells 
stained with tetramer (red) or 
negative control solution 
(without tetramer), CD8 (green) 
and DAPI (blue nuclear 
staining). a Spleen from a non-
infected mouse stained with 
speciWc tetramer showing an 
occasional very bright tetramer 
positive cell (red). b Spleen 
from a virus-infected mouse 
stained with speciWc tetramer 
showing clusters of positive 
cells (not seen in non-infected 
mice or in negative control 
stainings). c Spleen from a virus-
infected mouse stained with neg-
ative control solution. d CD8 
Staining of spleen from an 
infected mouse123
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OVA-tetramers. To optimize MHC class I tetramer stain-
ing, a variety of conditions was tested, i.e., tetramer incu-
bation time and temperature, thickness of tissue section,
blocking steps to prevent unspeciWc binding, chemical
Wxation and signal enhancement. For the optimization
procedure, positive MHC class I tetramer staining was
compared with stainings in which MHC class I tetramers
were omitted.
The results demonstrated that the thickness of the tissue
sections is of importance for the signal intensity and
morphology of the tissue. For tetramer detection of LP9
cells, tissue cryosections of 8 m thick were found to yield
a good speciWc signal with adequate morphology (Fig. 1g–l).
Thinner (5 m) or thicker (10 m) sections resulted in a
weak speciWc signal and good morphology (5 m) or a
good speciWc signal and poorer morphology (10 m) (not
shown). An incubation time of 45 min at room temperature
with MHC class I tetramers appeared to be superior to over-
night incubation at 4°C for tissue sections when no chemi-
cal Wxation of the tissue was performed. However, when a
mild chemical Wxation (see below) was applied prior to
MHC class I tetramer incubation both conditions were sim-
ilarly eVective.
The use of normal goat serum as a blocking step prior to
MHC class I tetramer incubation resulted in an improved
signal to noise ratio; however, it also resulted in poorer
morphology when used on non-chemically Wxed tissue sec-
tions. Fixation of the tissue with 4% PFA before (3 min)
and after (20 min) incubation with MHC class I tetramers
resulted in stronger speciWc signals and improved morphol-
ogy (Fig. 1g–l). Fixation before MHC class I tetramer incu-
bation proved to be a crucial step; Wxation for considerable
longer times or higher concentrations of PFA or Wxation
with acetone or glutaraldehyde resulted in a strong reduc-
tion or even loss of the (speciWc) signal. The Wxation step
after MHC class I tetramer incubation merely stabilized the
interactions between the T cell receptors and MHC class I
tetramers. In summary, optimal speciWc MHC class I tetra-
mer staining with satisfactory morphology was achieved
when 8 m thick cryosections were shortly Wxed and prein-
cubated with normal goat serum prior to MHC class I tetra-
mer incubation and followed by Wxation.
A polyclonal rabbit serum recognizing the MHC class I
tetramer-associated streptavidin molecules provided signal
enhancement that resulted in improved visualization of the
speciWc CTL. On both cytospins and LP9-containing muscle
tissue sections excellent results were obtained with the ABC-
kit as a signal ampliWcation and visualization method
(Fig. 1c–e, i, l). Unfortunately, initial tests on murine spleens
and human tissue sections, revealed that this ampliWcation
and visualization method resulted in high background
signals. The background observed upon ampliWcation and
visualization with the ABC-kit in these tissues was most
likely due to biotin-based, non-speciWc interactions. There-
fore, an alternative biotin-independent, Xuorochrome-based
ampliWcation and detection method was also developed that
yielded excellent signal to noise ratios for those tissues in
which the biotin-based protocol was sub-optimal (Fig. 1m–o).
The established protocols as speciWed in the “Materials and
methods” were used for further experiments.
In situ detection of inXuenza virus-speciWc T cells in mice
To validate the developed protocol in a more physiological
setting, we applied the virus-infection model previously
used to demonstrate in situ tetramer staining on 200–500 m
thick viable tissue sections [14]. In this model, lymph node
cells of TCR transgenic mice speciWc for the H-2Db-
restricted inXuenza A virus NP366 epitope were transferred
to B6.Ly5.1 mice. Mice were then challenged with either
inXuenza A virus or with vehicle. Using our protocol, 8 m
Table 1 Overview of tetramer-
positive cells found in DTH 
biopsies from melanoma 
patients vaccinated with DC 
loaded with tyrosinase and 
gp100 peptide
DTH challenge Tetramers
Tyrosinase gp100154 gp100280 MART-1 HIVgag EBV
Patient 1 DC + gp100280 ¡ ¡ + ¡ ¡ ND
Patient 2 DC + gp100280 ¡ ¡ + ¡ ¡ ND
DC + 3 peptides ¡ ¡ ¡ ¡ ¡ ND
Patient 3 DC + 3 peptides + ¡ + ¡ ¡ ¡
DC + 3 peptides + KLH ¡ + + ¡ ND ¡
DC alone ¡ ¡ ¡ ¡ ND ¡
DC + KLH ¡ ¡ ¡ ¡ ND ¡
Patient 4 DC + 3 peptides ¡ + ¡ ¡ ND ¡
DC + 3 peptides + KLH ¡ + ¡ ¡ ND ¡
Patient 5 DC + 3 peptides + + ¡ ¡ ND ¡
DC + 3 peptides + KLH + + + ¡ ND ¡123
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injected B6.Ly5.1 mice were stained with inXuenza A
virus-speciWc MHC class I tetramers and CD8. As shown in
Fig. 2, spleens from virus-infected mice contained large
clusters of MHC class I tetramer-positive cells (Fig. 2b)
whereas only an occasional tetramer positive T cell was
detected in spleens from non-infected mice (Fig. 2a). No
MHC class I tetramer positive CD8+ T cells were detected
in spleens from virus-infected mice incubated with negative
control solution (Fig. 2c, d). These results indicate that the
developed MHC class I tetramer staining protocol speciW-
cally detected the viral speciWc T cells in 8 m tissue sections
equally eVective when compared with the 200–500 m thick
viable tissue sections [14].
Fig. 3 Comparison of MHC class I tetramer staining in situ and MHC
class I tetramer staining of cell suspensions or cytotoxic activity of
cultured T cells of same DTH biopsies from melanoma patients
vaccinated with peptide-loaded DC. Cryosections stained with MHC
class I tetramers (red), anti-CD8 (green) and DAPI (blue). DTH biopsy
(DC loaded with gp100:280) from patient 1. a Positive HLA-A2. 1-
gp100280 tetramer staining (red). b HLA-A2.1-gp100154 tetramer
staining. c Chromium release assay showing the lysis of HLA-A2.1-
positive BLM cells, transfected with gp100 and not the control trans-
fectant G250 by T cells cultured from the DTH biopsy. DTH biopsy
(DC loaded with 3 peptides and KLH) from patient 3. d Positive HLA-
A2.1-gp100280 tetramer staining. e Cryosection from the same area as
shown in d stained with HLA-A2.1-tyrosinase tetramer. f Tetramer
analysis by Xow cytometry of DTH-derived T cells. Depicted is the
side scatter on the x-axis (double staining with CD8 FITC might
interfere with the tetramer staining) and on the y-axis MHC class I tet-
ramer PE staining. DTH biopsy (DC loaded with 3 peptides and KLH)
from patient 4. g Positive HLA-A2.1-gp100154 tetramer staining.
h Cryosection from the same area as shown in g stained with HLA-
A2.1-gp100280 tetramer. i Chromium release assay showing the lysis of
HLA-A2.1-positive T2 cells, loaded with gp100:154 and not T2 cells
loaded with irrelevant, gp100:280 or tyrosinase peptides by T cells cul-
tured from the DTH biopsy. j Tetramer analysis by Xow cytometry of
DTH-derived T cells. Depicted is the forward scatter on the x-axis
(double staining with CD8 FITC might interfere with the tetramer
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in melanoma patients
To determine the applicability of the in situ MHC class I
tetramer staining protocol for monitoring the presence of
vaccine-related CTLs in melanoma patients, we studied
DTH biopsies obtained from melanoma patients participat-
ing in ongoing trials at the Radboud University Nijmegen
Medical Centre. In these trials melanoma patients are
treated with autologous in vitro-generated mature DC
loaded with two HLA-A2.1-restricted gp100 epitopes
(154–162 and 280–288), an HLA-A2.1-restricted tyrosi-
nase-derived epitope (369–377) and KLH [9, 10]. To inves-
tigate the immune response generated in the vaccinated
patients, DTH challenges were performed with mature DC
and biopsies (6 mm) were taken from positive DTH sites.
Eight m thick cryosections were cut from one half of
these DTH biopsies and stained according to the developed
protocol with a panel of relevant and non-relevant MHC
class I tetramers (Table 1) and/or CD8. Initially 3 DTH
biopsies from 2 patients (patient 1 and 2) were studied.
Both patients had received DTH with gp100280-loaded DCs
and one patient also received a DTH with DCs loaded with
both gp100 peptides and the tyrosinase peptide (DC + 3
peptides). In patients speciWc staining of clusters of cells
with the HLA-A2.1-gp100280 tetramer was observed
whereas no staining with the negative control or any other
MHC class I tetramer was detected (Table 1; Fig. 3a–f). In
an additional 8 biopsies from 3 patients, MHC class I tetra-
mer positive cells were found in correspondence with the
DTH challenge speciWcity, e.g., peptide-speciWc T cells in
DTH sites arising from a challenge with DC loaded with
peptides and not in DTH sites from unloaded or KLH
loaded DC (Fig. 3g–i; Table 1).
SpeciWc T cells after short term culturing of DTH biopsies
Following a brief culture period, the speciWcity of T cells
derived from half of the biopsy was analyzed by conven-
tional methods, e.g., antigen recognition in a cytotoxicity
assay or MHC class I tetramer binding. Only a minority of
the DTH-derived cells were CD8 positive eVector T cells.
Fig. 4 DiVerential distribution of MHC class I tetramer-positive cells.
In the middle, a low magniWcation of an H&E stained tissue section
from patient 3 is shown. On each site of the H&E staining a CD4, CD8
and the designated MHC class I tetramers of representative areas are
shown123
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cultures varied between biopsies and patients (65 § 21%
CD4+ and 27 § 20% CD8+). In 9 out of the 11 biopsies
studied, identical T cell speciWcity was observed with the
in situ MHC class I tetramer staining and the assays
performed on the biopsy outgrowth (Fig. 3c, f, i, j). In the
other two cases (patient 2: DC + 3 peptides, patient 5:
DC + 3 peptides) peptide-speciWc T cells were only identi-
Wed with one of the assays. As exempliWed in Fig. 4, not all
cell clusters within a biopsy or tissue section harbor T cells
with the same speciWcity. Since the in situ analysis and
in vitro assays were performed on diVerent halves of the
biopsies some sampling bias may occur. Also some selec-
tion of speciWc clones may arise from the brief culture
period of the T cells.
CD8 staining
We noted that not all MHC class I tetramer-positive cells
were clearly CD8-positive. Variation of the exposure time
for the FITC Wlter (visualizing CD8+ cells) revealed a huge
range in staining intensities for CD8+ cells (Fig. 5) as also
noticed by Denkberg et al. [11]. An increased exposure
time for the green Wlter further increased the number
of CD8-positive, MHC class I tetramer-positive cells.
Competitive binding between CD8 and MHC class I tetra-
mer was also indicated by MHC class I tetramer binding
tests of cells in suspension. As shown in Fig. 5, MHC class
I tetramer staining intensity was reduced when the same
population of cells was co-stained with CD8 as compared
to co-staining with CD4. While for staining of cells in sus-
pension with MHC class I tetramer, samples were incu-
bated at the same time with MHC class I tetramer and CD8,
for the in situ protocol, samples were Wrst stained with
MHC class I tetramer followed by staining with CD8. This
explains possible reduced staining intensity for CD8 in the
in situ protocol, and reduced MHC class I tetramer staining
intensity for the in vitro staining protocol. In addition, a
direct comparison between CD8 staining eYciency in our
MHC class I tetramer staining protocol and the more con-
ventional CD8 staining method after acetone Wxation
revealed a major diVerence. As shown in Fig. 5 on tissue
sections from tonsils, fewer and less intensely stained
CD8+ cells are seen with the MHC class I tetramer staining
protocol.
Although we can not exclude that a small part of the
MHC class I tetramer-positive, CD8-negative cells result
from non-speciWc binding of MHC class I tetramer to other
non-CD8+ inXammatory cells, our Wndings indicate that:
(a) MHC class I tetramer binding only occurred in
accordance with the DTH challenge speciWcity, (b) MHC
class I tetramer-positive cells were not found using the
non-relevant MART-1, HIV and EBV tetramers, only with
the tyrosinase and gp100 tetramers, (c) no tyrosinase or
gp100-positive cells were found in DTH lesions derived
from non-speciWc challenges (i.e., DC alone [n = 4] or DC
loaded with KLH [n = 3]), (d) diVerent staining patterns
were obtained with the speciWc MHC class I tetramers and
Fig. 5 CD8 staining eYciency. DTH biopsy from patient 5 (lesion
DC + 3 peptides) stained with HLA-A2.1-tyrosinase369 tetramer (red),
anti-CD8 (green) and DAPI (blue) with increasing exposure time for
the FITC Wlter (ranging from 2–3 s (a) to 15–20 s (c), for comparison:
exposure time TRITC 7–8 s). Arrows indicate CD8+ cells that were not
visible at shorter exposure times for the FITC Wlter. In c, only for the
boxed area an increased exposure time (15–20 s) is shown to prevent
overexposure from other parts of the section. d Enlarged two color
overlay for green (CD8) and blue (DAPI) of the boxed area from c. Tet-
ramer analysis by Xow cytometry of DTH-derived T cells from patient
5. On the y-axis MHC class I tetramer PE staining and on the x-axis
CD4 (e) or CD8 (f). Note the diVerence in Xuorescence intensity in the
tetramer positive population (MFI CD4:152 vs. MFI CD8:83) whereas
the percentage of positive cells is equal (17%). CD8+ cells visualized
with the ABC-peroxidase kit with AEC (red-brown staining) as sub-
strate in corresponding areas on tissue sections from tonsil Wxed with
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T cell speciWcity clearly argue against a major involve-
ment of non-speciWc binding. It is, however, important to
include appropriate controls for the in situ detection of
CTLs.
In earlier studies, in situ detection of antigen-speciWc
T cells with MHC class I tetramers was performed on
viable tissue sections of spleens of T cell receptor trans-
genic mice or spleens of mice adoptively transferred with
speciWc T cells [14, 29, 30]. The application of this
method was extended to human T cells in a skin explant
assay for graft-versus-host CTL activity [12, 33]. A
drawback of the method described in those studies is that
it does not allow storage whereas storage of clinical
material facilitates retrospective analyses. With the use
of multimeric peptide/MHC class I complexes the need
for viable material is circumvented, however, these tetra-
mers are not readily available [2, 27, 31]. Therefore the
method as we describe, although intricate, is very useful
for the analyses of already frozen material from patients
treated with peptide-based vaccines. Therefore we believe
that this tetramer-based detection of antigen-speciWc
T cells in frozen tissue sections may provide a valuable
monitoring tool.
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